___

• Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS et al. (2020). Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: An immunoinformatics approach. BioMed Research International doi: 10.1101/2020.02.04.934232
• Acar T, Arayıcı PP, Ucar B, Karahan M, Mustafaeva Z (2019). Synthesis, characterization and lipophilicity study of Brucella abortus’ immunogenic peptide sequence that can be used in the future vaccination studies. International Journal of Peptide Research and Therapeutics 25: 911-918.
• Ahmed SF, Quadeer AA, McKay MR (2020). Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12: 254.
• Ali M, Pandey RK, Khatoon N, Narula A, Mishra A et al. (2017). Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Scientific Reports 7: 1-13.
• Almofti YA, Abd-elrahman KA, Gassmallah SAE, Salih MA (2018). Multi epitopes vaccine prediction against severe acute respiratory syndrome (SARS) coronavirus using immunoinformatics approaches. American Journal of Microbiological Research 6: 94-114.
• Amanat F, Krammer F (2020). SARS-CoV-2 vaccines: Status report. Immunity 52 (4): 583-589. doi: 10.1016/j.immuni.2020.03.007
• Bahrami AA, Payandeh Z, Khalili S, Zakeri A, Bandehpour M (2019). Immunoinformatics: In silico approaches and computational design of a multi-epitope, immunogenic protein. International Reviews of Immunology 38: 307-322.
• Baruah V, Bose S (2020). Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐ nCoV. Journal of Medical Virology 92: 495-500.
• Behrendt R, White P, Offer J (2016). Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science 22: 4-27.
• Bhattacharya M, Ranjan Sharma A, Patra P, Ghosh P, Sharma G et al. (2020). Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. Journal of Medical Virology 92 (6). doi: 10.1002/ jmv.25736
• Biswas S, Chatterjee S, Dey T, Dey S, Manna S et al. (2020). In silico approach for peptide vaccine design for CoVID 19. MOL2NET 2020, International Conference on Multidisciplinary Sciences, 6th edition session, USINEWS-04: US-IN-EU Worldwide Science Workshop Series, UMN, Duluth, USA, 2020.
• Bojin F, Gavriliuc O, Margineanu M-B, Paunescu V (2020). Design of an epitope-based synthetic long peptide vaccine to counteract the novel China Coronavirus (2019-nCoV). Preprints.
• Brian D, Baric R (2005). Coronavirus genome structure and replication. In: Enjuanes L (editor). Coronavirus Replication and Reverse Genetics. Springer, pp. 1-30.
• Bui H-H, Sidney J, Li W, Fusseder N, Sette A (2007). Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 8: 361. doi: 10.1186/1471-2105-8-361
• Callaway E (2020). The race for coronavirus vaccines: a graphical guide. Nature 580: 576-577. doi: 10.1038/d41586-020-01221-y
• Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). Features, evaluation and treatment coronavirus (COVID-19). In: Statpearls [internet]. StatPearls Publishing
• Chan W, White P (1999). Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford, UK: Oxford University Press.
• Channappanavar R, Zhao J, Perlman S (2014). T cell-mediated immune response to respiratory coronaviruses. Immunologic Research 59 (1): 118-128. doi: 10.1007/s12026-014-8534-z
• Chen W-H, Strych U, Hotez PJ, Bottazzi ME (2020). The SARSCoV-2 vaccine pipeline: an overview. Current Tropical Medicine Reports 3: 1-4. doi: 10.1007/s40475-020-00201-6
• Cho H, Excler J-L, Kim JH, Yoon I-K (2018). Development of Middle East respiratory syndrome coronavirus vaccines–advances and challenges. Human Vaccines & Immunotherapeutics 14 (2): 304-313. doi: 10.1080/21645515.2017.1389362
• Enjuanes L, Smerdou C, Castilla J, Antón IM, Torres JM et al. (1995). Development of protection against coronavirus induced diseases. In: Talbot PJ, Levy GA (editors). Corona-and Related Viruses. Boston, MA, USA: Springer, pp. 197-211.
• Fast E, Chen B (2020). Potential T-cell and B-cell epitopes of 2019- nCoV. bioRxiv. doi: 10.1101/2020.02.19.955484
• Feng Y, Qiu M, Zou S, Li Y, Luo K et al. (2020). Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2). bioRxiv. doi: 10.1101/2020.03.03.962332
• Gao Q, Bao L, Mao H, Wang L, Xu K et al. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science. doi: 10.1126/science.abc1932
• Glenny A, Pope C, Waddington H, Wallace U (1926). Immunological notes. xvii–xxiv. The Journal of Pathology and Bacteriology 29: 31-40. doi: 10.1002/path.1700290106
• Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B et al. (2020). A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARSCoV-2. Cell Host & Microbe 27 (4): 671-680. doi: 10.1016/j. chom.2020.03.002
• Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM et al. (1920). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. doi: 10.1016/j.cell.2020.05.015
• Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D et al. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research 7 (1):1-10. doi: 10.1186/s40779- 020-00240-0
• Guy B (2007). The perfect mix: recent progress in adjuvant research. Nature Reviews Microbiology 5 (7): 505-517. doi: 10.1038/ nrmicro1681
• Huang C, Wang Y, Li X, Ren L, Zhao J et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395 (10223): 497-506. doi: 10.1016/S0140- 6736(20)30183-5
• Jensen KJ, Shelton PT, Pedersen SL (2013) Peptide Synthesis and Applications. New York, USA: Springer.
• Jespersen MC, Peters B, Nielsen M, Marcatili P (2017). BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Research 3 (45): W24-W29. doi: 10.1093/nar/gkx346
• Joshi A, Joshi BC, Mannan MA-u, Kaushik V (2020). Epitope based vaccine prediction for SARS-COV-2 by deploying immunoinformatics approach. Informatics in Medicine Unlocked 19. doi: 10.1016/j.imu.2020.100338
• Kalita P, Padhi A, Zhang KY, Tripathi T (2020). Design of a peptidebased subunit vaccine against novel coronavirus SARSCoV-2. Microbial Pathogenesis 145: 104236. doi: 10.1016/j. micpath.2020.104236
• Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW et al. (2007). Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine 25 (4): 729-740. doi: 10.1016/j.vaccine.2006.08.011
• Khan M, Khan S, Ali A, Akbar H, Sayaf AM et al. (2019). Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Scientific Reports 9: 1-13. doi: 10.1038/s41598-019-49354-z
• Khong H, Overwijk WW (2016). Adjuvants for peptide-based cancer vaccines. Journal for immunotherapy of Cancer 4: 56. doi: 10.1186/s40425-016-0160-y
• Kibria K, Ullah H, Miah M (2020). The multi-epitope vaccine prediction to combat Pandemic SARS-CoV-2, an immunoinformatic approach.
• Kin N, Miszczak F, Lin W, Gouilh MA, Vabret A (2015). Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intraspecific diversity with new recombinant genotypes. Viruses 7 (5): 2358-2377. doi: 10.3390/v7052358
• King AM, Lefkowitz E, Adams MJ, Carstens EB (2011) Virus taxonomy: ninth report of the International Committee on Taxonomy of Viruses. Nucleic Acids Research 4: D708-717. doi: 10.1093/nar/gkx932
• Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y (2020). Bioinformatic prediction of potential T cell epitopes for SARSCov-2. Journal of Human Genetics 65: 596-575. doi: 10.1038/ s10038-020-0771-5
• Kolaskar A, Tongaonkar PC (1990). A semi‐empirical method for prediction of antigenic determinants on protein antigens. FEBS Letters 276 (1-2): 172-174. doi: 10.1016/0014-5793(90)80535-q
• Kumar S, Nyodu R, Maurya VK, Saxena SK (2020) Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection. In: Saxena SK (editor) Coronavirus Disease 2019 (COVID-19) Medical Virology: From Pathogenesis to Disease Control. Singapur: Springer. pp 43-53.
• Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S et al. (2020). The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery 19: 305-306. doi: 10.1038/ d41573-020-00073-5
• Lee CH-J, Koohy H (2020). In silico identification of vaccine targets for 2019-nCoV. F1000Research 9: 145. doi: 10.12688/ f1000research.22507.2
• Li L, Sun T, He Y, Li W, Fan Y et al. (2020). Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. bioRxiv. doi: 10.1101/2020.02.25.965434
• Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK (2014). Peptide vaccine: progress and challenges. Vaccines 2 (3):515- 536. doi: 10.3390/vaccines2030515
• Li X, Geng M, Peng Y, Meng L, Lu S (2020). Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis 10 (2): 102-108. doi: 10.1016/j. jpha.2020.03.001
• Lixin L, Zhijia L, Haolin C, Hong L, Qiang G et al. (2020). A translatable subunit nanovaccine for COVID-19. chemRxiv. Lon JR, Bai Y, Zhong B, Cai F, Du H (2020). Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2. bioRxiv. doi: 10.1101/2020.04.03.022723
• Lu S (2020). Timely development of vaccines against SARSCoV-2. Emerging Microbes & Infections 9 (1): 542-544. doi: 10.1080/22221751.2020.1737580
• Ma C, Su S, Wang J, Wei L, Du L et al. (2020). From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes and Infection. doi: 10.1016/j.micinf.2020.05.004
• Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD et al. (2018). Matrix-M™ adjuvant enhances immunogenicity of both protein-and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunologic Research 66 (2): 224- 233. doi: 10.1007/s12026-018-8991-x
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS et al. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395 (10229): 1033-1034. doi: 10.1016/S0140-6736(20)30628-0
• Merrifield RB (1963). Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society 85 (14): 2149-2154. doi: 10.1021/ja00897a025
• Moisa AA, Kolesanova EF (2012). Synthetic peptide vaccines. In: Roy PK (editor). Insight and Control of Infectious Disease in Global Scenario. pp. 201-228.
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B et al. (2011). Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29 (13): 2461-2473. doi: 10.1016/j. vaccine.2011.01.011
• Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M et al. (2003). Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21 (19-20): 2616-2626. doi: 10.1016/s0264- 410x(03)00040-9
• Navas-Martin S, Weiss SR (2003). SARS: lessons learned from other coronaviruses. Viral Immunology 16 (4): 461-474. doi: 10.1089/088282403771926292
• Nomura R, Kiyota A, Suzaki E, Kataoka K, Ohe Y et al. T (2004). Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae. Journal of Virology 78 (16): 8701-8708. doi: 10.1128/JVI.78.16.8701-8708.2004
• Oany AR, Emran A-A, Jyoti TP (2014). Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach. Drug Design, Development and Therapy 8: 1139-1149. doi: 10.2147/DDDT.S67861
• Ohno S, Kohyama S, Taneichi M, Moriya O, Hayashi H et al. (2009). Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice. Vaccine 27 (29): 3912-3920. doi: 10.1016/j.vaccine.2009.04.001
• Ozkan K (2020). How close are we to a Covid-19 vaccine. Journal of Pure and Applied Microbiology 14.
• Pant S, Singh M, Ravichandiran V, Murty U, Srivastava HK (2020). Peptide-like and small-molecule inhibitors against Covid-19. Journal of Biomolecular Structure and Dynamics 1-15. doi: 10.1080/07391102.2020.1757510
• Parvizpour S, Pourseif MM, Razmara J, Rafi MA, Omidi Y (2020). Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discovery Today S1359- 6446(20)30113-6. doi: 10.1016/j.drudis.2020.03.006
• Petrovsky N, Aguilar JC (2004). Vaccine adjuvants: current state and future trends. Immunology and Cell Biology 82 (5): 488-496. doi: 10.1111/j.0818-9641.2004.01272.x
• Pourseif MM, Yousefpour M, Aminianfar M, Moghaddam G, Nematollahi A (2019). A multi-method and structure-based in silico vaccine designing against Echinococcus granulosus through investigating enolase protein. BioImpacts 9 (3): 131- 144. doi: 10.15171/bi.2019.18
• Powell BS, Andrianov AK, Fusco PC (2015). Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clinical and Experimental Vaccine Research 4 (1): 23-45. doi: 10.7774/cevr.2015.4.1.23
• Rauch S, Jasny E, Schmidt KE, Petsch B (2018). New vaccine technologies to combat outbreak situations. Frontiers in Immunology 9: 1963. doi: 10.3389/fimmu.2018.01963
• Ravichandran S, Coyle EM, Klenow L, Tang J, Grubbs G et al. (2020). Antibody repertoire induced by SARS-CoV-2 spike protein immunogens. bioRxiv. doi: 10.1101/2020.05.12.091918
• Reed SG, Bertholet S, Coler RN, Friede M (2009). New horizons in adjuvants for vaccine development. Trends in Immunology 30 (1): 23-32. doi: 10.1016/j.it.2008.09.006
• Rogers TF, Zhao F, Huang D, Beutler N, Burns A et al. (2020). Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: 10.1101/2020.05.11.088674
• Roper RL, Rehm KE (2009). SARS vaccines: where are we? Expert Review of Vaccines 8 (7): 887-898. doi: 10.1586/erv.09.43
• Saif LJ (2020). Vaccines for COVID-19: perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines. European Medical Journal. doi: 10.33590/emj/200324
• Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA (2017). Fundamentals and methods for T- and B-cell epitope prediction. Journal of Immunology Research 2017:2680160. doi: 10.1155/2017/2680160
• Sesardic D (1993). Synthetic peptide vaccines. Journal of Medical Microbiology 39: 241-242.
• Shang W, Yang Y, Rao Y, Rao X (2020). The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. npj Vaccines 5: Article number: 18.
• Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R (2020). COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research 24: 91- 98. doi: 10.1016/j.jare.2020.03.005
• Shi J, Zhang J, Li S, Sun J, Teng Y et al. (2015). Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases. PloS one 10 (12): e0144475. doi: 10.1371/journal.pone.0144475
• Sobolev BN, Olenina LV, Kolesanova EF, Poroikov VV, Archakov AI (2005). Computer design of vaccines: approaches, software tools and informational resources. Current Computer-Aided Drug Design 1:207-222.
• Stawikowski M, Fields GB (2012). Introduction to peptide synthesis. Current Protocols in Protein Science 69 (1). doi: 10.1002/0471140864.ps1801s69
• Swee LK, Guimaraes CP, Sehrawat S, Spooner E, Barrasa MI et al. (2013). Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proceedings of the National Academy of Sciences 110 (4): 1428-1433. doi: 10.1073/pnas.1214994110
• Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S (2020). Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. Antiviral Research 178: 104792. doi: 10.1016/j.antiviral.2020.104792
• Thiel V, Weber F (2008). Interferon and cytokine responses to SARScoronavirus infection. Cytokine & Growth factor Reviews 19 (2): 121-132. doi: 10.1016/j.cytogfr.2008.01.001
• Tomar N, De RK (2010). Immunoinformatics: an integrated scenario. Immunology 131 (2): 153-168. doi: 10.1111/j.1365- 2567.2010.03330.x
• Tomar N, De RK (2014). Immunoinformatics: a brief review. In: De RK, Tomar N (editors) Immunoinformatics. Springer, pp 23- 55.
• Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T et al. (2012). Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one 7 (4): e35421. doi: 10.1371/journal. pone.0035421
• Ucar B, Acar T, Arayici PP, Sen M, Derman S et al. (2019). Synthesis and applications of synthetic peptides. In: Varkey JT (editor) Peptide Synthesis. IntechOpen.
• van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J et al. (2020). ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. doi: 10.1101/2020.05.13.093195
• Veugelers R, Zachmann G (2020). Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution.
• Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S et al. (2019). The immune epitope database (IEDB): 2018 update. Nucleic Acids Research 47 (D1): D339-D343. doi: 10.1093/nar/gky1006
• Wang N, Wei C, Zhang Z, Liu T, Wang T (2020). Aluminum nanoparticles acting as a pulmonary vaccine adjuvantdDelivery system (VADS) able to safely elicit robust systemic and mucosal immunity. Journal of Inorganic and Organometallic Polymers and Materials. doi: 10.1007/s10904-020-01572-z
• Wang Y-D, Sin W-YF, Xu G-B, Yang H-H, Wong T-Y et al. (2004). T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. Journal of Virology 78 (11): 5612-5618. doi: 10.1128/JVI.78.11.5612- 5618.2004
• Wu SC (2020). Progress and concept for COVID‐19 vaccine development. Biotechnology Journal. doi: 10.1002/ biot.202000147
• Yang H, Kim DS (2015) Peptide immunotherapy in vaccine development: from epitope to adjuvant. Advances in Protein Chemistry and Structural Biology 99: 1-14. doi: 10.1016/ bs.apcsb.2015.03.001
• Ying L, Xu S, Yang RF, Li YX, Ji YY et al. (2003). Identification of an epitope of SARS-coronavirus nucleocapsid protein. Cell Research 13 (3): 141-145. doi: 10.1038/sj.cr.7290158
• Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Frontiers in Microbiology 10: 1781. doi: 10.3389/fmicb.2019.01781
• Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K et al. (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. doi: 10.1126/science.abc6284
• Zhang G, Pomplun S, Loftis AR, Loas A, Pentelute BL (2020). The first-in-class peptide binder to the SARS-CoV-2 spike protein. bioRxiv. doi: 10.1101/2020.03.19.999318
• Zhang J, Zeng H, Gu J, Li H, Zheng L et al. (2020). Progress and prospects on vaccine development against SARS-CoV-2. Vaccines 8 (2): 153. doi: 10.3390/vaccines8020153
• Zhang N, Li C, Hu Y, Li K, Liang J et al. (2020). Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes and Infection. doi: 10.1016/j.micinf.2020.05.001
• Zhang X, Cai H, Hu J, Lian J, Gu J et al. (2020). Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. International Journal of Infectious Diseases 94: 81-87. doi: 10.1016/j.ijid.2020.03.040
• Zhao G, Lin Y, Du L, Guan J, Sun S et al. (2010). An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virology Journal 7: 9. doi: 10.1186/1743-422X-7-9
• Zhao K, Wang H, Wu C (2011). The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848. Vaccine 29 (38): 6670-6678. doi: 10.1016/j. vaccine.2011.06.100
• Zhou G, Zhao Q (2020). Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. International Journal of Biological Sciences 16: 1718-1723. doi: 10.7150/ijbs.45123